Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
19F MRI for Lung Function in Lung Cancer Radiotherapy
NCT03315065Phase 1Completed
- Sponsor
- Hal C Charles
- Start
- Feb 2018
- Primary completion
- Jun 2019
- Modality
- GAS (Genetic analysis systems)
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of perflutren in lung cancer, sponsored by Hal C Charles. Primary endpoints: Number of study patients consented at 4 months and Proportion of study patients that successfully return for a re-assessment 19F MRI scan after completing radiotherapy. Started Feb 2018; status: completed.
02
Drugs
perflutren
03
Conditions
lung cancer
Beyond the preview
Go deeper on NCT03315065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03315065.